165 related articles for article (PubMed ID: 26448071)
1. First US biosimilar launch.
Nat Biotechnol; 2015 Oct; 33(10):1013. PubMed ID: 26448071
[No Abstract] [Full Text] [Related]
2. First biosimilar drug approved in the USA.
Burki TK
Lancet Oncol; 2015 Apr; 16(4):e161. PubMed ID: 25773170
[No Abstract] [Full Text] [Related]
3. Emerging Opportunities and Challenges of Biosimilars in Oncology Practice.
Lyman GH
J Oncol Pract; 2017 Sep; 13(9_suppl):7s-9s. PubMed ID: 28898591
[No Abstract] [Full Text] [Related]
4. Japanese regulatory authority's perspective on biosimilars.
Nagai S; Yanagihara R; Kishioka Y
Lancet Oncol; 2015 Mar; 16(3):e101. PubMed ID: 25752552
[No Abstract] [Full Text] [Related]
5. Japanese regulatory authority's perspective on biosimilars - authors' reply.
Bennett CL; Chen B; Hermanson T; Georgantopoulos P; Sartor OA
Lancet Oncol; 2015 Mar; 16(3):e102. PubMed ID: 25752553
[No Abstract] [Full Text] [Related]
6. New frontiers in oncology: biosimilar monoclonal antibodies for the treatment of breast cancer.
Thill M
Expert Rev Anticancer Ther; 2015 Mar; 15(3):331-8. PubMed ID: 25539719
[TBL] [Abstract][Full Text] [Related]
7. The Biosimilar Pipeline Seams Seem To Be Bursting.
Reinke T
Manag Care; 2017 Mar; 26(3):24-25. PubMed ID: 28510516
[TBL] [Abstract][Full Text] [Related]
8. First biosimilar drug approved for sale in the United States.
Hede K
J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 26142444
[No Abstract] [Full Text] [Related]
9. First biosimilar drug set to enter US market.
Ledford H
Nature; 2015 Jan; 517(7534):253-4. PubMed ID: 25592512
[No Abstract] [Full Text] [Related]
10. FDA approves biosimilar version of infliximab.
Traynor K
Am J Health Syst Pharm; 2016 May; 73(10):604-6. PubMed ID: 27147206
[No Abstract] [Full Text] [Related]
11. Biosimilar Treatments Have Practice Implications.
Wiley K
ONS Connect; 2016 Apr; 31(4):38. PubMed ID: 27209660
[No Abstract] [Full Text] [Related]
12. Rationale, Opportunities, and Reality of Biosimilar Medications.
Lyman GH; Zon R; Harvey RD; Schilsky RL
N Engl J Med; 2018 May; 378(21):2036-2044. PubMed ID: 29791832
[No Abstract] [Full Text] [Related]
13. Biosimilar safety considerations in clinical practice.
Choy E; Jacobs IA
Semin Oncol; 2014 Feb; 41 Suppl 1():S3-14. PubMed ID: 24560025
[TBL] [Abstract][Full Text] [Related]
14. Developing oncology biosimilars: an essential approach for the future.
Abraham J
Semin Oncol; 2013 Dec; 40 Suppl 1():S5-24. PubMed ID: 24267944
[TBL] [Abstract][Full Text] [Related]
15. Obstacles to the Adoption of Biosimilars for Chronic Diseases.
Hakim A; Ross JS
JAMA; 2017 Jun; 317(21):2163-2164. PubMed ID: 28459924
[No Abstract] [Full Text] [Related]
16. FDA approves first biosimilar, zarxio.
Colwell J
Cancer Discov; 2015 May; 5(5):460. PubMed ID: 25790983
[No Abstract] [Full Text] [Related]
17. First US biosimilar edges towards market.
Senior M
Nat Biotechnol; 2015 Mar; 33(3):222-3. PubMed ID: 25748898
[No Abstract] [Full Text] [Related]
18. Maintaining 'standards' for biosimilar monoclonal antibodies.
Prior S; Metcalfe C; Hufton SE; Wadhwa M; Schneider CK; Burns C
Nat Biotechnol; 2021 Mar; 39(3):276-280. PubMed ID: 33664522
[No Abstract] [Full Text] [Related]
19. Forum discusses biosimilars, better biologicals.
Thompson CA
Am J Health Syst Pharm; 2011 Dec; 68(23):2210. PubMed ID: 22095804
[No Abstract] [Full Text] [Related]
20. Launching biosimilar rituximab: an industry opinion on biosimilar uptake in Europe.
Trollope R; Johnson S; Ireland H
Immunotherapy; 2017 Jun; 9(7):527-529. PubMed ID: 28523951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
